Interleukin(IL)-10 and IL-22 are structurally related cytokines. Their heterodimeric receptors consist of the cytokine-specific chains IL-10R1 and IL-22R1, respectively, and the common chain IL-10R2. This study focused on the question of whether IL-10 modulates IL-22 effects and vice versa. This question is important because IL-10 and IL-22 exert anti-and proinflammatory effects, respectively, and, as we show here, are simultaneously present in both systemic and local inflammation. The revealed lacking concomitance of IL-10R1 and IL-22R1 on identical cells excluded any possible interaction between IL-10 and IL-22 apart from the competition for IL-10R2. To study this competition, monocytes and hepatocytes were chosen. The dependence of the cytokine action on IL-10R2 was verified. Interestingly, no influence of IL-22 on IL-10 effects was observed. The same was true when IL-22 was used in complex with IL-22-binding protein. Similarly, no influence of IL-10 was found on IL-22 action. This missing competition seemed to be due to a lack of binding between IL-10R2 and the native cytokines in the absence of their corresponding R1 chain. However, IL-10R2 interacted with defined IL-10-and IL-22-derived peptides supporting the hypothesis that cytokine binding to its corresponding R1 chain creates a binding site on this cytokine for IL-10R2.
Introduction
The initiation, progression, and termination of all immunological processes are controlled by cytokines. Different cytokines often act simultaneously on one cell and may mutually modulate their effects. Interleukin(IL)-10 is one of the most important immunoregulatory cytokines with mainly anti-inflammatory and immunosuppressive effects. 1 Monocytes and macrophages are the major targets of this mediator. In these cells, IL-10 inhibits the production of proinflammatory cytokines and chemokines and downregulates the expression of MHC class II and costimulatory molecules thereby repressing the T-cell-stimulating capacity of these cells. [2] [3] [4] [5] [6] [7] [8] [9] Furthermore, IL-10 increases the surface IgG receptor expression and promotes phagocytosis by monocytes. 10 All these IL-10 effects are mediated by the IL-10 receptor complex that consists of ligand-specific IL-10R1 and accessory IL-10R2. 11, 12 Binding of IL-10 to its receptor induces signal transduction via the Janus kinases-signal transducers and activators of transcription (STAT) pathway involving activation of Jak1 and Tyk2, followed by tyrosine phosphorylation of STAT1, STAT3, and in nonmyeloid cells, STAT5. 13, 14 Recently, a series of novel cytokines, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A/B, and IL-29 were discovered and grouped in the IL-10-interferon family. [15] [16] [17] The mediators of this family resemble each other in their primary sequence including conserved amino-acid residues important for the characteristic a-helical secondary structure. The encoding genes of these cytokines are located in the human genome in three clusters, the first cluster comprising the genes for IL-10, IL-19, IL-20, and IL-24 on chromosome 1q31-32, the second cluster including the IFN-g, IL-22 and IL-26-encoding genes located on human chromosome 12q15, and the third cluster comprising the genes for IL-28A/B, and IL-29 on chromosome 19q13. Like the IL-10 receptor, the functional receptors for the novel cytokines are associations of R1-and R2-type chains belonging to the cytokine receptor family class II. Interestingly, there is a partial sharing of receptor subunits or even whole receptors within this cytokine family.
In contrast to IL-10 whose biological activities have been extensively studied, little is known about the biological role of these novel cytokines. It is supposed that they play a rather proinflammatory role. 16, 17 Apart from IL-10 and the interferons, IL-22 is currently the bestcharacterized member of the IL-10-interferon family. 18 We have shown that activated T cells, primarily Th1 cells, as well as activated NK cells are a major source of IL-22. 19 IL-22 acts on tissue cells mainly of the skin and of the digestive and respiratory systems and enhances the innate, nonspecific immunity without directly affecting immune cells. 20 In keratinocytes, IL-22 transcriptionally increased the expression of b-defensin 2 and b-defensin 3. High levels of IL-22 were associated with strongly upregulated b-defensin expression in skin from patients with T-cell-mediated dermatoses such as psoriasis. 20 In liver cells, IL-22 induces mRNA expression of acute phase proteins, such as serum amyloid A (SAA), a1-antichymotrypsin, and haptoglobin in vitro und in vivo. 21 Moreover, it was suggested that IL-22 exhibits a hepatoprotective role in T-cell-mediated liver injury. 22 In pancreas acinar cells and in pancreas in vivo, IL-22 stimulation induces expression of pancreatitis-associated protein 1, a molecule associated with acute pancreatitis. 23 The IL-22 receptor complex consists of IL-22R1 and IL-10R2, the latter also being involved in IL-10 signaling. 21, 24, 25 Moreover, identical to IL-10, IL-22 induces activation of Jak1, Tyk2, STAT1, STAT3, and STAT5. 18, 20, 21, [24] [25] [26] The anti-and proinflammatory role of IL-10 and IL-22, respectively, raised the question of whether in physiological concentrations one cytokine interferes with the effect of the other on an individual cell. This question is especially interesting in view of the sharing of the IL-10R2 chain and identical signal transduction elements by IL-10 and IL-22, and was the focus of this study.
Results

Simultaneous presence of IL-10 and IL-22 in vivo?
Prerequisite for any interaction between the effects of IL-10 and IL-22 is the simultaneous presence of both cytokines. To investigate this, we analyzed the mRNA expression of IL-10 and IL-22 in various in vivo situations associated with activation of immune cells. First, the expression of both cytokines was studied in mice after i.p. injection of LPS, as a model of systemic inflammation, and after cutaneous application of croton oil as a model of local inflammation. As shown in Figure 1 , simultaneous expression of IL-10 and IL-22 in mouse spleen after LPS induction (Figure 1a) , as well as in mouse skin after croton oil application (Figure 1b ) was observed in a kinetic study for 48 h. Second, we analyzed skin from healthy donors and patients with psoriasis. As shown in Figure 1c , biopsies from patients with psoriasis showed elevated expression levels of both IL-10 and IL-22 relative to healthy donors. These observations indicate a concomitance of IL-10 and IL-22 at states of inflammation and therefore the potential of interactions between IL-10 and IL-22.
Concomitance of receptor complexes for IL-10 and IL-22 on one cell? Theoretically, a positive or negative interaction between the two cytokines on an individual cell is possible (i) when the active effect of one cytokine modulates the effect of the other cytokine (eg by alteration of receptor expression, by induction of suppressors of cytokine signaling, or by modulation of the expression of the same target gene) or (ii) by simple competition for the shared receptor chain. Since the prerequisite for the first possibility is the concomitance of functional receptor complexes for both cytokines on one cell, we analyzed the expression of IL-10R1, IL-10R2, and IL-22R1 in a variety of different cell types. Table 1 Modulation of IL-10 effects by the presence of IL-22? Using either a selective IL-10-sensitive or an IL-22-sensitive cellular system, we then tested in vitro the influence of IL-22 on IL-10 effects and vice versa. As IL-10-sensitive cells we chose primary human monocytes, whose functional active receptor expression has been demonstrated before. 1 In accordance with previous reports, Figure 2a shows very high expression levels of IL-10R1 and IL-10R2, 1 but no expression of IL-22R1 in these cells. 19, 20 Among the various IL-10 effects on monocytes, we selected the decrease of cell surface MHC class II expression, the increase of cell surface Fcg R expression, and the decrease of production of proinflammatory cytokines. In fact, stimulation of peripheral blood mononuclear cells (PBMCs) with already 2 ng/ml IL-10 resulted in a clear decrease of HLA-DR expression and an increase of CD16 expression on monocytes after 24 h, as analyzed by means of flow cytometry (FCM), as well as a decrease of TNF-a production induced by 3 h LPS stimulation as quantified by enzyme-linked immunosorbent assay (ELISA) (Figure 2b ). The IL-10 concentration was chosen by where it lies in the concentration range of the EC 50 for the indicated effects. As expected from the absent IL-22R1 expression, IL-22 (at various concentrations ranging from 1 to 32 ng/ml) did not show these effects (Figure 2b , Wolk et al 20 and data not shown). To confirm that these IL-10 effects are IL-10R2 dependent, we performed IL-10 incubation in the presence of increasing concentrations of neutralizing anti-IL-10R2 antibodies (Abs) or respective control Abs. As shown in Figure 2c , the IL-10 effect on all investigated parameters was prevented in a dose-dependent manner in the presence of anti-IL-10R2 Abs but not of IgG, confirming the expected dependence of IL-10 effects on IL-10R2. Interestingly, there was a stronger prevention of the increase of CD16 expression than on the decrease of HLA-DR and TNF-a expression.
We then tested whether IL-22 could inhibit the action of IL-10 with respect to the selected IL-10 effects on monocytes. The presence of increasing concentrations of IL-22 during the IL-10 stimulation did not show any modulation of IL-10 effects, even at a 16-fold molar excess of IL-22 compared to (monomeric) IL-10 ( Figure 3a ).
IL-22 seems to be present in vivo not only as a free cytokine, but probably also in complex with IL-22-binding protein (BP). IL-22BP is a soluble, nonsignaling single-chain receptor which specifically binds IL-22 and was shown to prevent its effect on IL-22-sensitive cells in vitro. [27] [28] [29] [30] As IL-22BP may potentially favor IL-22 binding to IL-10R2, for example, by changing IL-22's structural conformation, we investigated whether IL-22, preincubated with IL-22BP at increasing molecular ratios (1 : 0.5 to 1 : 4), could modulate IL-10 effects. The activity of these IL-22BP concentrations was initially confirmed (see Materials and methods section). As shown in Figure 3b , IL-10 stimulation in the presence of IL-22 at the highest prior tested concentration (32 ng/ml, Figure 3a ), preincubated with increasing concentrations of IL-22BP also did not result in modulation of the IL-10-induced increase of CD16 nor the decrease of HLA-DR and TNF-a expression.
Modulation of the IL-22 effect by the presence of IL-10
For IL-22-sensitive cells, we chose the human HepG2 hepatocyte carcinoma cell line. 21 Receptor expression analysis confirmed sensitivity of these cells towards IL-22, but no expression of IL-10R1 was detected ( Figure 4a ). Based on published data showing the ability of IL-22 to induce SAA-specific mRNA in liver cells, 21 we tested IL-22-dependent SAA production at the protein level. We found a clear detectable SAA protein level, but only upon costimulation with IL-1b and TNF-a (Figure 4b and data not shown). The EC 50 of this effect was observed at about 10 ng/ml IL-22 (data not shown). IL-10, at various concentrations ranging from 5 to 160 ng/ml, did not induce SAA expression in these cells (Figure 4b and data not shown).
To confirm that the IL-22-induced SAA protein expression was IL-10R2 dependent, we performed IL-22 incubation (10 ng/ml) in the presence of increasing concentrations of neutralizing anti-IL-10R2 Abs or respective control Abs. As shown in Figure 4c , the IL-22 effect was prevented in a dose-dependent manner in the presence of the anti-IL-10R2 Abs, but not of IgG, confirming the expected dependence of IL-22 action on IL-10R2. To test whether IL-10 could inhibit the action of IL-22 in HepG2 cells, IL-22 stimulation was performed in the presence of increasing concentrations of IL-10. IL-10 presence did not show any modulation of the IL-22 effect, even at a 16-fold molar excess of (monomeric) IL-10 compared to IL-22 ( Figure 5 ).
Identification of binding sites for interaction of IL-10 and IL-22 with the common IL-10R2 One possible explanation for the lack of competition for the shared receptor chain might be a lack of direct binding of IL-10 and IL-22 to IL-10R2 in the absence of the respective R1 chain. To further examine this possibility, we analyzed the binding between the cytokines and IL-10R2 using scans of overlapping peptides (peptide scans). First, we investigated binding of the native IL-10R2 to peptides derived from IL-10 and IL-22 primary sequence. These peptides (15-mers peptides with two consecutive peptides overlapping by 13 amino acids) were prepared as arrays on cellulose membranes by SPOT synthesis. As shown in Figure 6a , binding of IL-10R2 to peptides derived from IL-10 and IL-22 was clearly detectable. However, when we analyzed binding of native cytokines to sets of 13 amino acids overlapping 15 amino acid long peptides derived from IL-10R2 primary sequence, no actual binding of native IL-10 and native IL-22 was observed (Figure 6b ). These data suggest that native IL-22 alone and native IL-10 alone are not able to bind to IL-10R2, but that interaction between these cytokines and IL-10R2 occur Human PBMCs were cultured in the presence of either 2 ng/ml IL-10, 32 ng/ml IL-22, or medium (control). After 24 h, analysis of monocytic CD16 and HLA-DR surface expression was performed by means of FCM. For analysis of TNF-a production capacity, after the first hour of culture LPS was added, and culture was continued for 3 h. Concentration of TNF-a in cell culture supernatants was then assessed by the Immulite s system. Data from three independent experiments are given as the mean 7s.e.m. (c) Human PBMCs were cultured with or without (control) 2 ng/ml IL-10 in the presence of increasing concentrations of neutralizing anti-IL-10R2 Abs or respective control Abs. After 24 h, analysis of monocytic CD16 and HLA-DR surface expression was performed by means of FCM. For analysis of TNF-a production capacity after the first hour of culture, LPS was added, and the culture was continued for 3 h. Concentration of TNF-a in cell culture supernatants was then assessed by the Immulite s system. Data from three independent experiments are given as percent of control (mean 7s.e.m.).
using an amino-acid sequence of these cytokines which is not normally accessible on the surface. . [15] [16] [17] Interestingly, different cytokines within that family share receptor chains or even whole receptor complexes. [31] [32] [33] [34] [35] Although little is known about the function of the novel IL-10-related cytokines, it seems that they do not play an IL-10-like biological role. IL-22, the best-characterized novel member of this family so far, is even considered as a proinflammatory cytokine due to its ability to induce b-defensins in keratinocytes, acute phase proteins in hepatocytes, and pancreatitisassociated protein-1 in pancreas acinar cells. and HLA-DR surface expression was performed by means of FCM. For analysis of TNF-a production capacity, after the first hour of culture, LPS was added, and the culture was continued for 3 h. Concentration of TNF-a in cell culture supernatants was then assessed by the Immulite s system. Data from three independent experiments are given as percent of control (mean7s.e.m.). (b) To assess the influence of IL-22 complexed with IL-22BP on IL-10 effects, human PBMCs were cultured as described in (a) with the exception that IL-22 was used at a fixed concentration (32 ng/ml), pre-incubated with increasing concentrations of IL-22BP for 2 h. Monocyte CD16, HLA-DR, and TNF-a expression was assessed as described in (a). Data from three independent experiments are given as percentage of control 7s.e.m.
Is there an interaction between IL-10 and IL-22? K Wolk et al and IL-22, apart from that by competition for the common IL-10R2 chain, was excluded by demonstrating the lack of concomitance of functional receptor complexes for both cytokines on individual cells (Table 1 , Figure 2a and 4a). To address the possible competition for the IL-10R2 chain, we used monocytes and hepatocytes as representatives of IL-10-and IL-22-sensitive cell populations, respectively. The dependence of IL-10 and IL-22 effects on IL-10R2 was verified using neutralizing Abs (Figure  2c and 4c) . Interestingly, different cytokine effects had different sensitivities to IL-10R2 blockade. This was neither clearly cytokine or cell specific, nor specific for expression-inducing or inhibitory effects. However, parameters associated with anti-inflammatory effects are possibly less inhibited by the blockade of IL-10R2. This might account for decreased sensitivity of essential anti-inflammatory effects against interferences, such as a decrease of density or availability of IL-10R2 on the cell surface during inflammation.
Our investigation of a possible modulation of the IL-10 effects in monocytes by the presence of IL-22 was performed using IL-22 concentrations up to 32 ng/ml (corresponding to a 16-fold excess over IL-10). Nevertheless, no influence of IL-22 on the selected IL-10 effects could be observed (Figure 3a and b) . This is in line with the data previously published by Gurney's group. 23, 24 Furthermore, we did not find any interference with IL-22 action on HepG2 cells by IL-10 which was also used at concentrations up to a 16-fold excess over IL-22 ( Figure 5) .
A possible reason for the lacking interference could be a missing binding of the competing cytokine to the common IL-10R2 in absence of the R1 chain for the competing cytokine. We therefore analyzed binding between the cytokines and IL-10R2 using peptide scans. Native IL-10R2 was able to bind defined peptides of the peptide scan derived from the IL-10 primary sequence and defined peptides of the peptide scan derived from the IL-22 primary sequence (Figure 6a ). Regarding the IL-10 peptide scan, especially the peptides 10-15 representing regions of helix A and the AB loop showed clear binding activity (Table 2 ). It appears therefore that IL-10R2 recognizes a region of the IL-10 molecule neighboring or overlapping to that recognized by IL-10R1. 36, 37 Regarding the IL-22 peptide scan, our data revealed clear binding of native IL-10R2 to the peptides 6, and 42-45, representing regions of helix A1 and the A1A2 loop (peptide 6), and helix D and the DE loop (peptides 42-45) ( Table 2) . As deduced from structural data, 38 these two segments in primary sequence form a discontinuous epitope in the IL-22 molecule. Interestingly, this discontinuous epitope is located next to a region which has been proposed as binding site for IL-22R1. 38 To our knowledge, these data represent the first experimental data that show the R2-binding site of a member of the IL-10 family.
In contrast to the clear binding of IL-10R2 to cytokinederived peptides, no interaction could be demonstrated of native IL-10 or native IL-22 to peptide scans derived from the IL-10R2 primary sequence using the same method (Figure 6b ). These data suggest that native IL-22 and native IL-10 alone are not able to bind significantly to IL-10R2, but that interaction between these cytokines Is there an interaction between IL-10 and IL-22? K Wolk et al (11) LRDLRDAFSRVKTFF (12) QEVVPFLARLSNRLS (42) DLRDAFSRVKTFFQM (13) VVPFLARLSNRLSTC (43) RDAFSRVKTFFQMKD (14) PFLARLSNRLSTCHI (44) AFSRVKTFFQMKDQL (15) LARLSNRLSTCHIEG (45) Is there an interaction between IL-10 and IL-22? K Wolk et al towards IL-22R1, whereas IL-10R2 exhibits no actual affinity for IL-22 alone but a substantial increase in affinity for the IL-22/IL-22R1 complex. 40 Very recently, Fouser's group has also shown that biotinylated IL-22 binds IL-22R1-Fc homodimer but not IL-10R2-Fc homodimer in an ELISA-based format, and that IL-10R2 stabilizes the association of IL-22 with IL-22R1. 42 Interestingly, binding of, for example, monoclonal Abs to defined areas of IL-10 or IL-22 increased the following binding of other proteins to these cytokines. 39, 42 This is further evidence that the binding of ligands can result in a conformational change of the IL-10 and the IL-22 molecule. If this is the case, our data would imply that such a conformational change of IL-22 can not be achieved through its prior binding to IL-22BP (Figure 3b) Another theoretical possibility for the lacking interference between IL-10 and IL-22 might be that IL-10 and IL-22 use different binding sites on IL-10R2. This possibility, however, is rather improbable as the threedimensional structures of cytokine receptor family type 2 members characterized so far demonstrate identical cytokine-binding area. 36, 43 Very recently, IL-10R2 was shown to function also as the R2-type chain in the receptor complexes for IL-26, IL-28A/B, and IL-29. [33] [34] [35] It would be interesting to investigate whether a competition for the common IL-10R2 by these cytokines can also be excluded.
Taken together, this study shows that, despite their concomitance, IL-22 und IL-10 do not interact. Furthermore, our data support the hypothesis that the members of the IL-10 family are able to bind their low-affinity receptor chain only after initial binding of their highaffinity receptor chain.
Materials and methods
Cell culture
Human PBMCs from healthy donors were isolated from venous blood and cultured as previously described. 44 For gene expression analyses, monocytes were isolated from PBMCs by negative selection using the MACSt system (Miltenyi Biotec, Bergisch-Gladbach, Germany). As judged by FCM (see below), the purity of monocyte fractions was at least 92%. Macrophages and dendritic cells were generated by culturing isolated monocytes for 5 days in the presence of 10 ng/ml M-CSF (R&D Systems, Wiesbaden, Germany) and for 7 days in the presence of 10 ng/ml GM-CSF/10 ng/ml IL-4 (both from R&D Systems), respectively. The cell lines Jurkat, THP-1, HL60, C170, Hep G2, A549, MDA-MB-231, BxPC-3, and A3 sub E were purchased from the European Collection of Cell Cultures (Salisbury, UK) and maintained according to the supplier's instructions. HaCaT cells, kindly provided by NE Fusenig (Deutsches Krebsforschungszentrum, Heidelberg, Germany), were cultured in DMEM supplemented with 10% (v/v) fetal bovine serum and 4 mM glutamine (all from Biochrom KG, Berlin, Germany). For functional assays total PBMCs were exposed or not (control) to 2 ng/ml IL-10 or 32 ng/ ml IL-22 (both from R&D Systems). For FCM, IL-10 and IL-22 exposition was performed for 24 h. For assessment of LPS-induced TNF-a production, 100 ng/ml LPS from Escherichia coli 0127:B8 (Sigma, Taufkirchen, Germany) or the equivalent volume of medium were added after the first hour of IL-10 or IL-22 exposition, and culture was continued for 3 h. To confirm the dependence of IL-10 effects on IL-10R2, IL-10 exposition of PBMCs was performed in the presence of increasing concentrations of anti-IL-10R2 polyclonal Abs (0, 0.1, 0.32, 1, 3.2, 10 mg/ ml) or respective control Abs (polyclonal mouse IgG) (both from R&D Systems). To test whether IL-22 could inhibit IL-10 effects, IL-10 exposition of PBMCs was performed in the presence of increasing concentrations of IL-22 (0, 1, 3.2, 10, 32 ng/ml) (R&D Systems). To study the influence of IL-22/IL-22BP complexes on IL-10 effects, IL-10 exposition of PBMCs was performed in the presence of 32 ng/ml IL-22 pre-incubated for 2 h with increasing concentrations of IL-22BP (0, 74, 148, 296, 592 ng/ml) (R&D Systems). For experimental procedure, HepG2 cells were seeded at 50 000 cells/cm 2 and precultured for 48 h. After subsequent media change, cells were exposed or not (control) to 10 ng/ml IL-22 or 160 ng/ml IL-10 each in the presence of 10 ng/ml IL-1b and 10 ng/ml TNF-a (R&D Systems). The presence of IL-1b and TNF-a served to increase constitutive and stimulation-induced HepG2 SAA production up to levels above the SAA detection limit of the used ELISA method. To confirm the dependence of the IL-22 effect on IL-10R2, IL-22 exposition was performed in the presence of increasing concentrations of anti-IL-10R2 polyclonal Abs (0, 0.1, 0.32, 1, 3.2, 10 mg/ml) or respective control Abs (polyclonal mouse IgG). To test whether IL-10 could inhibit the IL-22 effect, exposition to IL-22 was performed in the presence of increasing concentrations of IL-10 (0, 5, 16, 50, 160 ng/ml). To confirm the biological activity of IL-22BP, HepG2 cells, in the presence or absence of costimulation as described above, were exposed to IL-22 and IL-22BP at increasing concentrations (0, 23.3, 46.7, 93.3, and 186.6 ng/ml IL-22BP) that had been pre-incubated together for 2 h.
Mice
Male BALB/c mice were purchased by Charles River (Wilmington, MA, USA), and were used at the age of 96-110 days. To study LPS-induced systemic inflammation, mice were i.p. injected with 5 mg/g mouse LPS from E. coli 0111:B4 (Sigma-Aldrich Chemie, Taufkirchen, Germany). Directly before (0 h), and 1, 3, 6, 24, and 48 h after LPS injection mice were killed, and spleen samples were taken. To study croton oil-induced skin inflammation, 25 ml of 1% (v/v) croton oil in ethanol/isopropyl myristate (19 : 1) (Sigma-Aldrich Chemie) were applied to the leg. After killing mice, skin samples from the treated leg were taken prior to treatment (0 h) and 1, 3, 6, 24, and 48 h afterwards.
Skin biopsies
Punch biopsies (5-6 mm) were obtained from diseased skin from adult patients with chronic plaque psoriasis or from healthy skin of control participants. These biopsies were approved by the Clinical Institutional Review Board of the university hospital Charité Berlin, and consent was obtained from all participants.
